logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
H

Hiroki Ishihara

Tokyo Women's Medical University
H指数:24
被引数:2,488

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma

比较卡博替尼联合纳武利尤单抗与伦伐替尼联合帕博利珠单抗在转移性肾细胞癌患者中的临床结局

International Urology and Nephrology
IF1.9
2026-01-010
OA
Nakamura, Kazutaka; Yoshida, Kazuhiko; Kobari, Yuki; Nemoto, Yuki; Ishihara, Hiroki; Fukuda, Hironori; Iizuka, Junpei; Shimmura, Hiroaki; Kobayashi, Hiroshi; Hashimoto, Yasunobu; Kondo, Tsunenori; Takagi, Toshio
Outcomes of tyrosine kinase inhibitor monotherapy for advanced renal cell carcinoma arising in patients with kidney transplantation: comparison with sporadic and end-stage renal disease populations

酪氨酸激酶抑制剂单药治疗在肾移植患者中发生的晚期肾细胞癌中的疗效：与散发性和终末期肾病人群的比较

Clinical and Experimental Nephrology
IF1.7
2025-12-010
PRE
Katsurayama, Nanaka; Ishihara, Hiroki; Hirai, Toshihito; Saito, Ayaka; Okada, Daigo; Unagami, Kohei; Fukuda, Hironori; Yoshida, Kazuhiko; Omoto, Kazuya; Iizuka, Junpei; Shimizu, Tomokazu; Kondo, Tsunenori; Ishida, Hideki; Takagi, Toshio
Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma

比较纳武利尤单抗联合伊匹木单抗与乐伐替尼联合帕博利珠单抗或纳武利尤单抗联合卡博替尼联合疗法在既往未治疗的晚期肾细胞癌中的真实世界结局

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
IF2.3
2025-09-012
PRE
Ishihara, Hiroki; Omae, Kenji; Nemoto, Yuki; Mizoguchi, Shinsuke; Katsurayama, Nanaka; Nakayama, Takayuki; Fukuda, Hironori; Yoshida, Kazuhiko; Shimmura, Hiroaki; Hashimoto, Yasunobu; Iizuka, Junpei; Kondo, Tsunenori; Takagi, Toshio
Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma

起始剂量酪氨酸激酶抑制剂对免疫检查点抑制剂联合酪氨酸激酶抑制剂治疗初治晚期肾细胞癌后结局的影响

JAPANESE JOURNAL OF CLINICAL ONCOLOGY
IF2.2
2025-09-010
PRE
Ishihara, Hiroki; Nishimura, Koichi; Nemoto, Yuki; Mizoguchi, Shinsuke; Nakayama, Takayuki; Fukuda, Hironori; Shimmura, Hiroaki; Hashimoto, Yasunobu; Yoshida, Kazuhiko; Iizuka, Junpei; Kondo, Tsunenori; Takagi, Toshio
Sex differences in immunotherapy outcomes and tumor-infiltrating immune cell profiles in patients with advanced renal cell carcinoma

免疫疗法结局和肿瘤浸润免疫细胞表型在晚期肾细胞癌患者中的性别差异

CANCER IMMUNOLOGY IMMUNOTHERAPY
IF5.1
2025-01-030
OA
Ishihara, Hiroki; Fukuda, Hironori; Mizoguchi, Yukihiro; Yamashita, Makiko; Aoki, Kazunori; Ishiyama, Ryo; Ikeda, Takashi; Nemoto, Yuki; Shimmura, Hiroaki; Hashimoto, Yasunobu; Yoshida, Kazuhiko; Hirai, Toshihito; Iizuka, Junpei; Tokita, Daisuke; Kondo, Tsunenori; Nagashima, Yoji; Takagi, Toshio
Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study
TARGETED ONCOLOGY
IF4
2023-03-217
PRE
Ishihara, Hiroki; Nemoto, Yuki; Nakamura, Kazutaka; Tachibana, Hidekazu; Ikeda, Takashi; Fukuda, Hironori; Yoshida, Kazuhiko; Kobayashi, Hirohito; Iizuka, Junpei; Shimmura, Hiroaki; Hashimoto, Yasunobu; Kondo, Tsunenori; Takagi, Toshio
Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma
TARGETED ONCOLOGY
IF4
2022-12-263
PRE
Ishihara, Hiroki; Nemoto, Yuki; Nakamura, Kazutaka; Tachibana, Hidekazu; Fukuda, Hironori; Yoshida, Kazuhiko; Kobayashi, Hirohito; Iizuka, Junpei; Shimmura, Hiroaki; Hashimoto, Yasunobu; Kondo, Tsunenori; Takagi, Toshio
Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study
TARGETED ONCOLOGY
IF4
2021-06-268
PREAI
Ishihara, Hiroki; Nemoto, Yuki; Nakamura, Kazutaka; Ikeda, Takashi; Tachibana, Hidekazu; Fukuda, Hironori; Yoshida, Kazuhiko; Kobayashi, Hirohito; Iizuka, Junpei; Shimmura, Hiroaki; Hashimoto, Yasunobu; Takagi, Toshio; Ishida, Hideki; Kondo, Tsunenori; Tanabe, Kazunari

研究方向

暂未获取到该数据
T
Toshio Takagi
H 指数:34论文数:511被引数:6,616
K
Kazuhiko Yoshida
H 指数:43论文数:584被引数:8,231
J
Junpei Iizuka
H 指数:24论文数:286被引数:2,371
H
Hironori Fukuda
H 指数:17论文数:245被引数:1,118
Y
Yuki Nemoto
H 指数:12论文数:69被引数:384
H
Hirohito Kobayashi
H 指数:30论文数:216被引数:3,629
T
Tsunenori Kondo
H 指数:34论文数:187被引数:3,707
H 指数:0论文数:182被引数:1,540
Y
Yasunobu Hashimoto
H 指数:22论文数:191被引数:1,592
T
Tsunenori Kondo
H 指数:25论文数:263被引数:2,177